China Pharma Holdings Files 8-K on Agreements and Equity Sales

TL;DR

China Pharma inked a deal and sold stock on Dec 4th. 8-K filed Dec 10th.

AI Summary

China Pharma Holdings, Inc. filed an 8-K on December 10, 2025, reporting on two key events that occurred on December 4, 2025: entering into a material definitive agreement and unregistered sales of equity securities. Specific details regarding the nature of the agreement and the equity sales were not provided in this excerpt.

Why It Matters

This filing indicates significant corporate actions, including potential new business deals and the issuance of new shares, which could impact the company's financial structure and future operations.

Risk Assessment

Risk Level: medium — The filing mentions unregistered sales of equity securities, which can sometimes indicate dilution or less transparent capital raising activities.

Key Players & Entities

• CHINA PHARMA HOLDINGS, INC. (company) — Registrant
• December 4, 2025 (date) — Earliest event reported
• December 10, 2025 (date) — Filing date

FAQ

Key Financial Figures

• $6.3 m — ice as contemplated by the Agreement is $6.3 million, which will be paid in the form o
• $0.001 — common stock of the Company, par value $0.001 per share (the " Common Stock "), at $1
• $1.80 — 01 per share (the " Common Stock "), at $1.80 per share. Item 3.02 Unregistered Sal

Filing Documents

• ea026901601-8k_chinapharma.htm (8-K) — 26KB
• 0001213900-25-120129.txt ( ) — 190KB
• cphi-20251204.xsd (EX-101.SCH) — 3KB
• cphi-20251204_lab.xml (EX-101.LAB) — 33KB
• cphi-20251204_pre.xml (EX-101.PRE) — 22KB
• ea026901601-8k_chinapharma_htm.xml (XML) — 4KB

01

Item 1.01 Entry into a Material Definitive Agreement. On December 4, 2025, Hainan Helpson Medical & Biotechnology Co., Ltd (" Helpson "), a wholly owned subsidiary of China Pharma Holdings, Inc. (the " Company "), entered into a Technology Transfer Agreement (the " Agreement ") with Lijie Tang (the " Transferor "). The Transferor owns an invention patent of a Captopril microcapsule and Method for Its Preparation (the " Invention Patent "). Pursuant to the Agreement, the Transferor will transfer the ownership of the Invention Patent to Helpson. The Transferor or its designated third party shall provide relevant technical services, which include but are not limited to product research and development, writing of registration materials, registration application and other technical services. The transfer price as contemplated by the Agreement is $6.3 million, which will be paid in the form of common stock of the Company, par value $0.001 per share (the " Common Stock "), at $1.80 per share.

02

Item 3.02 Unregistered Sales of Equity Securities. The information contained in Item 1.01 of this Current Report on Form 8-K in relation to the issuance of the Company's securities mentioned above is incorporated herein by reference. The Company is to issue an aggregate of 3,500,000 restricted shares of Common Stock in connection with the technology transfer. The Company's securities mentioned above, if and when issued, will not be registered under the Securities Act as amended (the " Securities Act "), or the securities laws of any state, and are being offered and issued in reliance on the exemption from registration under the Securities Act afforded by Regulation S promulgated thereunder for the issuance of the shares to the person who is a non-U.S. person as the securities are being issued to the person through an offshore transaction which was negotiated and consummated outside the United States.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: December 10, 2025 CHINA PHARMA HOLDINGS, INC. By: /s/ Zhilin Li Name: Zhilin Li Title: President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR